EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?

BACKGROUND: EGFR tyrosine kinase inhibitors (TKIs) have greatly improved the outcomes of EGFR mutation-positive adenocarcinomas of the lung. In contrast, the significance of EGFR mutation in metastatic squamous cell carcinoma (SCC) of the lung has been debated. METHODS: All patients with metastatic...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Onco Targets Ther
Autors principals: Joshi, Amit, Zanwar, Saurabh, Noronha, Vanita, Patil, Vijay M, Chougule, Anuradha, Kumar, Rajiv, Janu, Amit, Mahajan, Abhishek, Kapoor, Akhil, Prabhash, Kumar
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2017
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5378442/
https://ncbi.nlm.nih.gov/pubmed/28405166
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S125397
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars